drug
(amphetamine aspartate + amfetamine + dextroamphetamine saccharate + dextroamphetamine sulfate)
Marketedupdated 3mo agoby Actavis Elizabeth LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 24, 2029
~3.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Aug 24, 2029formulationUS 88461003.1y
- Aug 24, 2029formulationUS 88461003.1y
- Aug 24, 2029formulationUS 88461003.1y
- Aug 24, 2029formulationUS 88461003.1y
- May 12, 2026method-of-use (U-2025)US 9173857
- May 12, 2026method-of-use (U-2025)US 9173857
- May 12, 2026method-of-use (U-2025)US 9173857
- May 12, 2026method-of-use (U-2025)US 9173857
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that